

March 2008

Volume 13 · Numbers 5/6 pp. 189–278



Cover Story

The keynote review in this issue of Drug Discovery Today, by Antonio Llinàs and Jonathan M. Goodman, deals with the topic of control of crystal polymorphism in drug development. Single substances can exist in multiple crystal forms: some may be useful, some problematic and yet others, potentially dangerous. The formation of such polymorphs is no longer a mysterious or inexplicable process and the review addresses recent approaches to their control in active pharmaceutical ingredients.



REVIEWS

KEYNOTE

198 Polymorph control: past, present and future

Antonio Llinàs and Jonathan M. Goodman

GENE TO SCREEN

211 From a glucocentric to a lipocentric approach towards metabolic syndrome

Shivani Mittra, Vinay S. Bansal and Pradip K. Bhatnagar

INFORMATICS

219 Towards improving compound selection in structure-based virtual screening

Bohdan Waszkowycz

POST SCREEN

- 227 Helping science to succeed: improving processes in R&D
 Andreas Sewing, Toby Winchester, Pauline Carnell, David Hampton and Wilma Keighley
- 234 Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases

Gareth J. Sanger

240 Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies

Thomas K. Petersen and Poul Sørensen

247 Drug delivery from the oral cavity: focus on a novel mechatronic delivery device

Oliver A. Scholz, Andy Wolff, Axel Schumacher, Libero I. Giannola, Giuseppina Campisi, Tomasz Ciach and Thomas Velten

254 New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage

R. Webster Crowley, Ricky Medel, Neal F. Kassell and Aaron S. Dumont

261 Discovery of tight junction modulators: significance for drug development and delivery

Paul H. Johnson, Diane Frank and Henry R. Costantino

268 Advances in measuring cellular bioenergetics using extracellular flux

David A. Ferrick, Andy Neilson and Craig Beeson

